Abstract
Golgi α-mannosidase II, a key enzyme in N-glycan processing, is a target in the development of anticancer therapies. The crystal structure of Drosophila Golgi α-mannosidase II in the absence and presence of the anti-cancer agent swainsonine and the inhibitor deoxymannojirimycin reveals a novel protein fold with an active site zinc intricately involved both in the substrate specificity of the enzyme and directly in the catalytic mechanism. Identification of a putative GlcNAc binding pocket in the vicinity of the active site cavity provides a model for the binding of the GlcNAcMan5GlcNAc2 substrate and the consecutive hydrolysis of the α1,6- and α1,3-linked mannose residues. The enzyme-inhibitor interactions observed provide insight into the catalytic mechanism, opening the door to the design of novel inhibitors of α-mannosidase II.
| Original language | English |
|---|---|
| Pages (from-to) | 3008-3017 |
| Number of pages | 10 |
| Journal | EMBO Journal |
| Volume | 20 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 15 Jun 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer therapy
- Drug design
- Golgi α-mannosidase II
- N-glycosylation pathway
- X-ray crystallography
ASJC Scopus subject areas
- General Neuroscience
- Molecular Biology
- General Immunology and Microbiology
- General Biochemistry,Genetics and Molecular Biology
Fingerprint
Dive into the research topics of 'Structure of Golgi α-mannosidase II: A target for inhibition of growth and metastasis of cancer cells'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS